CA
NZ
UK
AU
IND
US
…
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -56.70M | -28.97M | -19.01M | -19.35M | -16.17M |
| Minority interest | 0.00M | 0.00M | -0.01M | -0.01M | 0.00M |
| Net income | -54.23M | -27.47M | -8.14M | -20.10M | -16.17M |
| Selling general administrative | 14.14M | 11.37M | 9.89M | 9.29M | 9.39M |
| Gross profit | 63.77M | - | - | - | - |
| Reconciled depreciation | 0.07M | 0.06M | 0.06M | 0.07M | 0.23M |
| Ebit | -57.60M | -29.05M | -19.14M | -20.09M | -16.16M |
| Ebitda | -58.58M | -29.15M | -19.08M | -19.29M | -15.94M |
| Depreciation and amortization | -0.98M | -0.10M | 0.06M | 0.81M | 0.23M |
| Operating income | -57.60M | -29.05M | -19.14M | -20.09M | -16.99M |
| Other operating expenses | 57.60M | 29.05M | 19.14M | 20.09M | 16.99M |
| Interest expense | 1.95M | 0.23M | 0.12M | 0.00M | 0.01M |
| Tax provision | -2.48M | -1.51M | -10.87M | 0.00M | 0.00M |
| Net interest income | - | - | - | 0.00M | -0.01M |
| Income tax expense | -2.48M | -1.51M | -10.87M | 0.75M | -0.00M |
| Total revenue | 121.37M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 57.60M | 29.05M | 19.14M | 20.09M | 16.99M |
| Cost of revenue | 57.60M | - | - | - | - |
| Total other income expense net | 0.90M | 0.08M | 0.13M | 0.74M | 0.82M |
| Net income from continuing ops | -54.23M | -27.47M | -8.14M | -19.35M | -16.17M |
| Net income applicable to common shares | - | -27.47M | -8.15M | -19.36M | -16.17M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 54.69M | 73.03M | 97.01M | 36.00M | 27.15M |
| Intangible assets | 0.26M | 0.33M | - | - | - |
| Other current assets | 2.39M | 2.65M | 1.21M | 0.76M | 0.81M |
| Total liab | 6.80M | 6.71M | 5.01M | 3.76M | 6.60M |
| Total stockholder equity | 48.15M | 66.58M | 92.25M | 32.50M | 20.82M |
| Other current liab | 4.00M | 3.55M | 2.36M | 2.12M | 1.60M |
| Common stock | 0.01M | 0.01M | 0.06M | 0.02M | 0.01M |
| Capital stock | 0.01M | 0.01M | 0.06M | 0.02M | 0.01M |
| Retained earnings | -528.08M | -507.24M | -453.02M | -425.55M | -417.40M |
| Other liab | - | - | - | - | 0.62M |
| Other assets | - | - | 1.21M | 0.04M | 0.17M |
| Cash | 22.59M | 32.15M | 24.65M | 16.51M | 14.03M |
| Total current liabilities | 6.59M | 6.38M | 4.52M | 3.51M | 5.98M |
| Current deferred revenue | - | - | - | - | 2.53M |
| Net debt | -22.29M | -31.67M | -23.93M | -15.89M | -13.68M |
| Short term debt | 0.17M | 0.18M | 0.23M | 0.37M | 0.35M |
| Short long term debt total | 0.30M | 0.48M | 0.71M | 0.62M | 0.35M |
| Other stockholder equity | 576.26M | 573.84M | 545.28M | 458.04M | 438.20M |
| Property plant equipment | - | - | 0.79M | 0.63M | 1.01M |
| Total current assets | 53.92M | 71.88M | 96.18M | 35.33M | 25.97M |
| Net tangible assets | - | - | 92.25M | 32.50M | 20.82M |
| Short term investments | 27.94M | 37.07M | 70.32M | 18.06M | 11.12M |
| Net receivables | 1.00M | - | - | - | - |
| Accounts payable | 2.42M | 2.65M | 1.93M | 1.02M | 1.49M |
| Accumulated other comprehensive income | -0.04M | -0.03M | -0.07M | -0.01M | 0.00M |
| Non currrent assets other | 0.02M | 0.53M | 0.76M | 0.61M | 1.08M |
| Non current assets total | 0.77M | 1.16M | 0.83M | 0.67M | 1.18M |
| Capital lease obligations | 0.17M | 0.48M | 0.71M | 0.62M | 0.35M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | 10.10M | 28.91M | -54.84M | -7.26M | 21.43M |
| Change to liabilities | - | - | 1.25M | -2.84M | -1.86M |
| Total cashflows from investing activities | - | - | -54.90M | -7.28M | 21.43M |
| Total cash from financing activities | 0.39M | -0.22M | 85.28M | 18.58M | 1.18M |
| Change to operating activities | - | - | -0.60M | 0.52M | 0.74M |
| Net income | -20.84M | -54.23M | -27.47M | -8.14M | -19.35M |
| Change in cash | -9.56M | 7.51M | 8.13M | 2.48M | 3.73M |
| Begin period cash flow | 32.15M | 24.65M | 16.51M | 14.03M | 10.30M |
| End period cash flow | 22.59M | 32.15M | 24.65M | 16.51M | 14.03M |
| Total cash from operating activities | -20.03M | -21.17M | -22.25M | -8.82M | -18.88M |
| Issuance of capital stock | 0.32M | 0.04M | 85.50M | 18.73M | 1.31M |
| Depreciation | 0.19M | 0.07M | 0.06M | 0.06M | 0.07M |
| Sale purchase of stock | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M |
| Other cashflows from financing activities | -0.09M | -0.27M | -0.22M | -0.15M | -0.13M |
| Change to netincome | - | - | 4.52M | 1.58M | 1.54M |
| Capital expenditures | 0.00M | 0.28M | 0.06M | 0.02M | 0.02M |
| Change in working capital | -0.46M | -0.83M | 0.65M | -2.32M | -1.12M |
| Stock based compensation | 2.04M | 2.64M | 2.00M | 1.26M | 1.29M |
| Other non cash items | 1.37M | 31.18M | 2.51M | 0.31M | 0.23M |
| Free cash flow | -20.03M | -21.45M | -22.30M | -8.84M | -18.88M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| LSTA Lisata Therapeutics Inc. |
-0.07 6.25% |
1.05 | - | - | - | 0.50 | 1.03 |
| NVO Novo Nordisk A/S |
-0.79 1.90% |
40.59 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-1.97 0.36% |
548.90 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-9.49 1.03% |
910.47 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
| Name | Title | Year Born |
|---|---|---|
| Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. | CEO & Director | 1957 |
| Dr. Kristen K. Buck M.D. | Exec. VP of R&D and Chief Medical Officer | 1974 |
| Mr. David Slack MBA | Pres, Chief Bus. Officer & Director | 1963 |
| Mr. James Nisco | VP of Fin. & Treasury | NA |
| Mr. Gregory S. Berkin | Chief Information Officer | NA |
| Mr. John D. Menditto | VP of Investor Relations & Corp. Communications | NA |
| Eric Powers | Director of Communications and Marketing | NA |
| Ms. Gail Holler | VP of HR | 1959 |
| Dr. Ian Zhang MBA, Ph.D. | Pres of NeoStem (China), Inc and Managing Director of NeoStem (China), Inc | 1965 |
| Dr. William K. Sietsema Ph.D. | VP of Global Regulatory Affairs | 1956 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.70%
Communication Services
-0.44%
Consumer Cyclical
-0.50%
Consumer Defensive
+0.08%
Energy
-0.07%
Financial Services
-0.35%
Financials
-2.20%
Healthcare
-0.95%
Industrials
-0.37%
Real Estate
-0.38%
Technology
-1.52%
Utilities
-0.57%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...